Showing 1-10 of about 89 articles.
Precision Biosciences
-PBCAR0191 continues to be associated with no serious adverse events or dose limiting toxicities observed to date, and no cases of graft-versus-host disease- -Seven of nine treated patients (78%)...
Incysus Therapeutics, Inc.
NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incysus Therapeutics, Inc.
NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Vineti
SAN FRANCISCO and PHILADELPHIA, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Vineti, a leading provider of a digital platform of record for personalized therapies, and WuXi AppTec Advanced Therapies, a...
Incysus Therapeutics, Inc.
NEW YORK, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Aldevron
Fargo, N.D, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Aldevron has announced the immediate availability of Nanoplasmids™ and antibiotic-free RNA-OUT technology for use in gene therapy manufacturing. Through...
Aldevron
Fargo, N.D., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Aldevron has announced the immediate availability of Nanoplasmids™ and antibiotic-free RNA-OUT technology for use in gene therapy manufacturing....
Incysus Therapeutics, Inc.
NEW YORK, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the...
Incysus Therapeutics, Inc.
NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Showing 1-10 of about 89 articles.
